Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check6 days agoChange DetectedAdds two new study update dates (2026-02-14 and 2026-02-17) and removes two earlier dates (2026-01-15 and 2026-01-16). No core trial details, including eligibility, interventions, or outcomes, appear to be changed.SummaryDifference0.2%

- Check14 days agoChange DetectedPage now shows Revision: v3.4.2 and the older Revision: v3.4.1 notice has been removed along with a government funding status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding notice banner about potential delays and that the NIH Clinical Center is open. Updated the page revision to v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary visibility is now shown and two QC-related metadata fields ('Last Update Submitted that Met QC Criteria' and 'Last Update Posted') are displayed, with the page revision updated to v3.4.0. The older entries 'Last Update Submitted that met QC Criteria' and 'Last Update Posted (Estimated)' were removed, along with the lowercase 'No FEAR Act data' in favor of capitalization 'No FEAR Act Data', and the revision was updated from v3.3.4 to v3.4.0.SummaryDifference0.3%

- Check35 days agoChange DetectedNew update timestamps were added for 2026-01-16 and 2026-01-15, while timestamps from 2025-12-08 and 2025-12-05 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 is now displayed on the page, replacing v3.3.3, with no other visible changes to study details.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.